 decoction inhibits the motility and tumorigenesis of colorectal cancer cells by unknown
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Geijigajakyak decoction inhibits the motility
and tumorigenesis of colorectal cancer cells
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Abstract
Background: Recent studies report that inflammatory diseases of the large intestine are associated with colorectal
cancer. Geijigajakyak Decoction (GJD) has antispasmodic and anti-inflammatory effects on the gastrointestinal tract.
Thus, in light of the connection between chronic bowel inflammation and colorectal cancer (CRC), we asked
whether GJD inhibits colorectal tumorigenesis.
Methods: The effects of GJD on the viability and proliferation of CRC cells were evaluated using MTT and
BrdU assays, respectively. The motility of CRC cells was examined by a Transwell migration/invasion assay
and immunoblot analysis was used to examine the signaling pathways associated with migration. A syngeneic
Balb/c mice allograft model, in which CT26 cells were injected into the dorsum, was used to evaluate the
anti-tumor effects of GJD in vivo.
Results: GJD had no cytotoxic effects against HCT116 CRC cells, although it did inhibit their proliferation.
GJD inhibited the migration of HCT116 cells, and suppressed the invasion of HCT116, Caco2, and CSC221
CRC cells. In addition, GJD downregulated the expression of p-JNK and p-p38 MAPK, which are downstream
signaling molecules associated with invasiveness. Furthermore, oral administration of GJD (333 mg/kg, twice
a day) inhibited tumor growth in a mouse xenograft model.
Conclusions: GJD inhibited the motility of human CRC cells and suppressed tumorigenesis in a mouse
model. These results suggest that GJD warrants further study as a potential adjuvant anti-cancer therapy.
Keywords: Colorectal cancer, Herbal medicine, Geijigajakyak decoction, Cell invasion, Tumorigenesis
Abbreviations: BrdU, 5-bromo-2-deoxyuridine; CAM, Complementary and Alternative Medicine; CRC, Colorectal
cancer; GJD, Geijigajakyak decoction; LC-MS, Liquid chromatography mass spectrometry; MTT, 3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide; PBS, Phosphate buffered saline; PE, Aqueous extract of paeoniae radix; PMA, Phorbol-
myristic acid; SYD, Shaoyao decoction
Background
Complementary and Alternative Medicine (CAM) is
popular with cancer patients today. CAM therapies are
not a main treatment for cancer, but they can be used
as adjuncts to conventional therapies such as radiother-
apy, chemotherapy, hormone therapy, and surgery [1, 2].
Herbal formulae have a long history as a form of CAM
therapy, and have engendered strong trust among those
that practice and receive Korean traditional medicine.
Today, some herbal formulations are thought to affect
multiple pharmacological targets; as such, they are ex-
pected to be a useful component of combination therapies
that show better efficacy and greater safety than single
compound-based drugs [3].
The Shanghanlun, an ancient Chinese medical report,
introduces the Geijigajakyak Decoction (GJD; Gui Zhi
Jia Shao Yao Tang) in the section dealing with greater
yin disease, which covers all diseases with symptoms
such as abdominal fullness, food accumulation, diarrhea,
and abdominal pain [4]. If patients with greater yin dis-
ease experience abdominal fullness and pain, GJD is pre-
scribed as the optimal drug; indeed, it is used to treat
many gastrointestinal diseases, including colitis. Recent
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studies report that GJD reduces abdominal pain by alter-
ing intestinal movement [5], and has significant anti-
inflammatory effects in rats with 2,4,6-trinitrobenzene
sulfonic acid-induced colitis by inhibiting smooth muscle
contraction and neutrophil chemotaxis [6]. Other studies
report that GJD has antispasmodic and antidepressant ef-
fects in those with irritable bowel syndrome [7], that it has
antidiarrheal effects [8], and that it relaxes gastrointestinal
smooth muscle [9, 10]. However, no study has examined
the effects of GJD on gastrointestinal cancer.
There are 1.2 million cases of colorectal cancer (CRC)
per year worldwide, with 600,000 deaths. Indeed, CRC is
the third most common cancer worldwide, and metastasis
is the major cause of death. The 5-year survival rate for
patients with distant metastasis at the time of diagnosis is
0–7 % [11]. Up-regulation of cancer cell motility is an
essential step in metastasis and tumor progression [12];
indeed, metastasis is the main cause of death in about
90 % of human cancer cases. Thus, inhibiting cancer cell
migration and invasion may suppress metastasis. We pre-
viously studied the effects of modulating gene expression
on progression of colorectal tumorigenesis via examining
cell motility and signaling in vitro and measuring tumor
growth in vivo in a syngeneic mouse model [13, 14].
Many studies suggest a strong correlation between colo-
rectal tumorigenesis and chronic bowel inflammation
[15–17], and several herbal prescriptions used to treat
gastrointestinal symptoms have been tested to see whether
they have any anti-cancer effects; for example, PHY906
has been tested as a modulator of chemotherapy [18],
as an adjuvant therapy for cancer [19], as a modulator
of irinotecan-based therapy [20], and as an attenuator
of chemotherapy-induced gastrointestinal toxicity [21].
Shaoyao Decoction (SYD), another herbal prescription,
improves colitis-associated CRC [22]. As GJD might
function as a complementary agent to alleviate chronic
bowel inflammation, and in light of the connection be-
tween chronic inflammation and CRC, we thus asked in
this study whether GJD suppresses CRC similar to PHY906
and SYD. Therefore, we investigated the effects of GJD on
colorectal tumorigenesis by examining cell motility and sig-
naling in vitro, and its effects in a syngeneic mouse tumor
model. We found that GJD inhibited the motility of CRC
cells in vitro and colorectal tumorigenesis in vivo.
Methods
Preparation of GJD
GJD comprises five commonly used herbs: Cinnamomi
Ramulus, Glycyrrhizae Radix, Paeoniae Radix, Zingiberis
Rhizoma, and Ziziphi Fructus. The raw herbs used to
prepare GJD were purchased from Omniherb (Additional
file 1: Table S1, Daegu, Korea) and mixed at a ratio of
3:6:2:3:3; the weight of each herb (gram, dry weight) is
18, 36, 12, 18, and 18 g, respectively (Table 1). Aqueous
extract of GJD was prepared by suspending the herb
mixture (total 102 g) in 1 l of distilled water and heat-
ing to 100 °C for 3 h in a water bath (KSB-55; Sunil De-
veloped ENG, CO., LTD., Korea). Aqueous extract of
Paeoniae Radix (PE) was also prepared by suspending
the herb (100 g, dry weight) in 1 l of distilled water
with the same method as GJD. The extracts were then
filtered through filter paper (Whatman™ Cat No. 1004
150; GE Healthcare, UK) and concentrated using a vacuum
evaporator (R124; Buchi Labortechnik AG, Switzerland). Fi-
nally, they were lyophilized by freeze-drying (FD 8508;
Ilshin Lab, CO., Ltd. Korea) and stored at −20 °C. GJD
powder was diluted in water prior to use. After dilution, the
solution was filtered through a 45 Ø filter and stored at
−20 °C. When added to culture media, the final volume
of GJD solution was limited to less than 5 % to prevent
osmotic shock.
Cell culture
Caco2, HCT116, and CT26 (colorectal cancer) cell lines
were purchased from the American Type Culture Collec-
tion (ATCC, Manassas, VA) and CSC221 (a colorectal
Table 1 Ingredients and doses of Geijigajakyak Decoction (GJD)




of decoction (in the
Shanghanlun)
Cinnamomi Ramulus Phenolic acids (cinnamic acid, protocatechuric acid),
coumarin, tannins, eugenol, 2-hydroxycinnamaldehyde
[2, 33–35] 18 9
Glycyrrhizae Radix Flavanones (dihydroflavones: liquiritin, liquirigenin),
licopyranocoumarins, 18β-glycyrrhetinic acid, isoliquiritigenin
[2, 36–38] 36 18
Paeoniae Radix Flavonols (astragalin), tannins (gallotannin), stilbenes
(resveratrol), adenosine, betulinic acid, oleanolic acid,
paeoniflorin, paeonol, α-tocopherol
[2, 25, 39–44] 12 6
Zingiberis Rhizoma Phenolic volatile oils (gingerol analogues: gingerols,
shogaols)
[2, 45–50] 18 9
Ziziphi Fructus 18 9
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cancer) cell line was purchased from the BioMedicure
(San Diego, CA). HCT116, Caco2, CSC221, and the CT26
murine colon cancer cell line were maintained at 37 °C in
a 5 % CO2 atmosphere in DMEM supplemented with
10 % FBS and 1 % penicillin/streptomycin. All cell lines
used in the study were authenticated by the ATCC and
BioMedicure using STR-PCR analysis.
Cell viability assay
Cell viability was measured in a 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay using
the EZ-Cytox Cell viability assay kit (Daeil Lab Service Co.,
Korea). Cells were treated with GJD and seeded in 96-well
flat bottomed plates at a density of 1 × 104 cells/100 ml.
The culture medium was removed after 24 or 48 h. Next,
10 μl of EZ-Cytox reagent and GJD-treated medium was
added to each well for another 4 h at 37 °C prior to mea-
surement of cell viability. The absorbance was determined
in an ELISA micro-plate reader at a test wavelength of
450 nm.
Cell proliferation assay
Cell proliferation was measured according to the level
of 5-bromo-2-deoxyuridine (BrdU) incorporation during
DNA synthesis. The assay was performed using the Cell
proliferation ELISA BrdU kit according to the manufac-
turer’s protocol (Roche, Mannheim, Germany). In brief,
1 × 104 cells were incubated with 100 μl of test compound
(0–1.0 mg/ml GJD) in 96-well flat bottomed plates for 24
or 48 h. Cells were then treated with BrdU labeling solu-
tion for 2 h. The culture medium was then removed, the
cells fixed, and DNA denatured. Cells were incubated with
Anti-BrdU-POD solution for 90 mins and antibody conju-
gates were removed through three washing cycles. Im-
mune complexes were detected by incubation with a TMB
substrate for 15 min and quantified by measuring the
absorbance at 390 nm and 472 nm. All tests were per-
formed in duplicate, with six wells per treatment group.
All experiments were repeated at least twice.
Cell migration and invasion assays
Cell migration and invasion were measured using a
Transwell apparatus as described previously [13]. Briefly,
to measure cell invasion, the top chamber of each well
of a 24 well Transwell chamber was coated overnight
at 37 °C with 1 % gelatin. Wells were not coated with
gelatin when measuring cell migration. After incuba-
tion, the gelatin solution was removed from the upper
chamber, which was then allowed to dry for 4 h. Medium
(500 μl), containing fibronectin as a chemoattractant, was
then added to the bottom chamber of each well. Cells
(1 × 105 or 2 × 10 in DMEM/0.2 % BSA) were seeded in
the upper chamber and incubated at 37 °C for 24 or
48 h. After incubation, the cells were stained and ex-
amined under a microscope (Leica Microsystems).
Western blot analysis
Western blot analysis was performed to examine the
cell signaling events affected by GJD. After treatment
with GJD, cells were lysed in RIPA Lysis buffer (25 mM
Tris · HCl, pH 7.6, 150 mM NaCl, 1 % NP-40, 1 % so-
dium deoxycholate, 0.1 % SDS) containing a protease
inhibitor cocktail (Sigma). Lysates were then incubated for
30 min on ice, followed by centrifugation for 10 min. The
protein concentration in the supernatants was measured
using a BCA protein assay reagent (Bio-Rad). Aliquots
were loaded onto SDS-electrophoresis gels, separated, and
transferred to a PVDF membrane. The membrane was
then immunoblotted with antibodies specific for Akt (Cell
Signaling), p-Akt (Cell Signaling), c-Jun (Cell Signaling),
ERK (Cell Signaling), p-ERK (Cell Signaling), p-JNK (Cell
Signaling), p-p38 MAPK (Cell Signaling), and β-actin
(Santa Cruz), followed by secondary antibodies conjugated
to horseradish peroxidase (Amersham). Reactive bands
were visualized by enhanced chemiluminescence using a
LAS 3000 (Fuji Film, Tokyo, Japan).
In vivo tumor growth
The CT26 cell/syngeneic mouse model was used to in-
vestigate the in vivo effects of GJD on colorectal tumori-
genesis, as it is reported that a syngeneic mouse tumor
model is a good for testing the anti-cancer effects of
candidate substances in short-term studies [11]. Male
Balb/c mice (5 weeks old) were purchased from DaMul
Science, Korea, and acclimated for 1 week prior to sub-
cutaneous injection of syngeneic CT-26 cells (2 × 105)
into the dorsum as previously described [14]. After 7 days,
tumors were palpable and mice were randomly assigned
to vehicle (PBS)-treated or GJD-treated groups (n = 7
mice/group). GJD (333 mg/kg; dose calculated to maintain
a serum concentration of 1.0 mg/ml) was orally adminis-
tered twice per day; control mice received PBS. The time
line of the protocol is outlined in Fig. 5a. The experimen-
tal protocol was approved by the Chonnam National Uni-
versity Medical School Research Institutional Animal Care
& Use Committee, and animals were maintained and all
experiments performed according to the Guiding Princi-
ples in the Care and Use of Animals (DHEW publication,
NIH 80-23). Tumor volume (V ) was calculated using the
following equation: V = 1/2×a×b2, where a and b are the
longest and shortest diameters of the tumor (in millime-
ters), respectively. Tumor volume was measured daily for
21 days to verify the effects of GJD. All mice were sacri-
ficed after Day 21, and the subcutaneous tumor grafts
were surgically excised and weighed.
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Liquid chromatography mass spectrometry (LC-MS)
analysis
Aqueous extract of GJD and aqueous extract of Paeoniae
Radix (PE) samples were analyzed using an Agilent LC-
1200 series instrument combined with an Agilent 6410
triple-quadrupole mass spectrometer (Agilent Technolo-
gies, USA) system. A YMC-Pack Pro C8 column (4.6 ×
150 mm, 3 μm, YMC, Japan) was coupled to the system
and the flow rate was set at 0.7 mL/min. The mobile
phases comprised 5 mM ammonium acetate in water
containing 0.1 % formic acid (A) and 5 mM ammonium
acetate in methanol containing 0.1 % formic acid (B). The
gradient was programmed as follows: 0–1 min, 70 % A;
1–5 min, 70–20 % A; 5–8 min, 20–5 % A; 8–13 min,
5 % A; 13–14 min, 5–70 % A; 14–25 min, 70 % A. The
injection volume was 5 μl. Mass spectrometry analysis
was performed in the multiple reaction monitoring with
negative-ion electrospray ionization (ESI-) mode. The
fragment electric voltage, collision energy, and quantifi-
cation of paeonol were achieved by monitoring the m/z
of precursor/product ions (Table 2). Synthesized paeo-
nol compound (Aldrich) was used as a standard for
calibration.
Statistical analysis
Experimental differences were tested for statistical signifi-
cance using ANOVA followed by Tukey’s HSD post-hoc
test or Student’s t test. All statistical tests were two-sided
and P-values <0.05 were considered significant. Statistical
analysis was performed using PASW Statistics 20 (SPSS)
software.
Results
GJD shows a mild anti-proliferative effect against CRC
cells
The effects of GJD on the viability of CRC cells were
measured in MTT assays. As shown in Fig. 1a, HCT116,
Caco2, and CSC221 cells showed differing viabilities in
the presence of increasing doses of GJD. The viability of
HCT116 cells cultured for 48 h in the presence of








Paeonol 165/150, 122 80 10
Fig. 1 GJD shows mild anti-proliferative effects against human colorectal cancer cells. a Cell viability was measured in an MTT assay and compared
with that of control (CON) cells. Each bar represents the mean ± SEM for triplicate samples. An asterisk indicates a significant difference between cells
treated with GJD and vehicle (PBS) (*P < 0.05, **P < 0.01). HCT116 cells (1 × 104 cells/well) were incubated with 0.001–1 mg/ml GJD for 48 h. Caco2
and CSC221 cells (1 × 104 cells/well) were incubated with 0.001–1 mg/ml GJD for 24 h. b Cancer cell proliferation was measured in a BrdU assay and
compared with that of control cells
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0.3 mg/ml GJD was 93.05 % of that of untreated con-
trols. By contrast, the viability of Caco2 and CSC221
cells in the presence of 0.3 mg/ml GJD for 24 h was
84.75 and 110.25 %, respectively, of that of untreated
controls. These results indicate that GJD was only very
mildly toxic at a concentration of 0.3 mg/ml.
As shown in Fig. 1b, the proliferation of HCT116
cells showed a dose-dependent decrease upon exposure
to GJD. At a concentration of 0.3 mg/ml, GJD sup-
pressed HCT116 proliferation to 89.81 % of that of
untreated controls. However, the proliferation of other
cells showed an inconsistent pattern. At 0.3 mg/ml,
GJD suppressed the proliferation of Caco2 cells to
81.96 % of that of untreated controls. By contrast, the
proliferation of CSC221 cells was unaffected at GJD
doses from 0.001 mg/ml to 0.3 mg/ml. These results
Fig. 2 GJD inhibits the motility of colorectal cancer cells. a GJD suppresses the migration of colorectal cancer cells. HCT116 cells were treated with
different concentrations of GJD (0.1 or 0.3 mg/ml) or with vehicle (PBS), and subjected to a migration assay: upper wells, 1 × 105 cells and 0.2 % BSA;
lower wells, 1 % FBS and 10 μl/ml fibronectin. After 48 h, cells were stained and analyzed. The images shown are representative of three independent
experiments. The histogram represents the number of migrating cells, which was counted in five chosen areas (mean ± SEM, n = 3). An asterisk
indicates a significant difference between the GJD and control groups (**P < 0.01). b GJD suppresses the invasion of colorectal cancer cells. HCT116,
Caco2, and CSC221 cells were treated with different concentrations of GJD (0.1 or 0.3 mg/ml) or vehicle (PBS) and subjected to an invasion assay.
HCT116 cells were incubated for 48 h: upper wells, 1 × 105 cells and 0.2 % BSA; lower wells, 1 % FBS and 10 μl/ml fibronectin. Caco2 and CSC221 cells
were incubated for 24 h: upper wells, 1 × 105 cells and 0.2 % BSA; lower wells, serum free medium and 10 μl/ml fibronectin. The histogram represents
the number of invading cells, which was counted in five chosen areas (mean ± SEM, n = 3). An asterisk indicates a significant difference between the
GJD and control groups (*P < 0.05, **P < 0.01)
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indicate that GJD has only a mild anti-proliferative
effect on human CRC cells. When CRC cell viability
and proliferation rates were compared at a concentra-
tion of 0.3 mg/ml GJD, we recorded values of 93.05 %
vs. 89.81 %, 84.75 % vs. 81.96 %, and 110.25 % vs.
99.93 % for HCT116, Caco2, and CSC221 cells, respec-
tively, indicating that GJD at 0.3 mg/ml suppresses cell
proliferation a little better than cell viability. In other
words, although GJD is not toxic to these cells, it does
suppress their proliferation. Thus, a concentration of
0.3 mg/ml GJD was selected as the optimal dose for
studying its anti-invasive effects against HCT116, Caco2,
and CSC221 cells.
GJD inhibits the migration and invasion of colorectal
cancer cells
A Transwell migration assay was used to evaluate
whether GJD affects the migration/invasion of HCT116
cells. HCT116 migration was 23.49 % of that of untreated
control cells in the presence of 0.3 mg/ml GJD, indicating
that GJD inhibits CRC migration. The results of the inva-
sion assays based on HCT116, Caco2, and CSC221 cells
showed that invasion decreased as the concentration of
GJD increased, i.e., the effect was dose-dependent (Fig. 2a).
As shown in Fig. 2b, GJD significantly inhibited the inva-
sion of HCT116, Caco2, and CSC221 cells at 0.3 mg/ml.
Invasion of HCT116, Caco2, and CSC221 cells in the
presence of 0.3 mg/ml GJD was 69.91, 63.50, and 85.78 %,
respectively, of that of untreated control cells. As shown
above, the viability of HCT116, Caco2, and CSC221 cells
in the presence of 0.3 mg/ml GJD was 93.05, 84.75, and
110.25 %, respectively, of that of untreated controls. Thus
GJD inhibited cell invasion regardless of cell viability.
Effect of GJD on the downstream signaling events
involved in HCT116 cell invasion
Next, we performed western blot analysis to examine the
cell signaling pathways responsible for the anti-invasive
phenotype conferred upon CRC cells by GJD. Changes in
the expression of Akt, p-Akt, ERK, p-ERK, c-jun, p-JNK,
and p-p38 were examined at 30 min and 2 h post-
treatment of HCT116 cells with 0.3 mg/ml GJD. As
shown in Fig. 3a, expression of p-JNK and p-p38 MAPK
decreased after exposure to GJD. It is well-known that
phorbol-myristic acid (PMA) activates protein kinase C
isozymes, which are upstream regulators of the MAP
kinase pathways, to promote tumor progression [23].
Therefore, we stimulated HCT116 with PMA to identify
the signaling molecules that play a role in the inhibitory
effects of GJD. HCT116 cells were treated with GJD for
1 h and then activated with PMA for 15 min. As shown in
Fig. 3b, GJD downregulated PMA-induced expression of
p-JNK, c-Jun, and p-p38. Thus, the inhibitory effect of
GJD is related to its ability to inhibit the phosphorylation
of JNK and p-38 MAPK.
GJD suppresses the proliferation and motility of CT26
murine colon cancer cells
CT26 cells were the first choice for studying the effect of
GJD on colorectal tumorigenesis in vivo because they are a
Fig. 3 Effects of GJD on the expression of p-JNK and p-38 MAPK in HCT116 cells. a HCT116 cells were treated with 0.3 mg/ml GJD for different
times (0, 0.5, or 2 h), after which Akt, p-Akt, ERK1/2, p-ERK1/2, c-Jun, p-c-Jun, p-JNK, and p-p38 levels were examined by western blotting.
b HCT116 cells were pretreated with 0.3 mg/ml GJD for 1 h before exposure to 100 nM PMA for 15 min. Whole cell lysates were then
subjected to immunoblot analysis as in (a)
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murine colon adenocarcinoma cell line that is tumorigenic
in Balb/c mice. CT26 viability was measured in an MTT
assay in the presence of different concentrations of GJD.
GJD at concentrations up to 1 mg/ml had no effect on cell
viability (97.29 % of that of untreated controls; Fig. 4a).
Therefore, a concentration of 1.0 mg/ml was selected for
further studies.
Proliferation of CT26 cells in the presence of different
concentrations of GJD was measured in a BrdU assay.
In contrast to cell viability, GJD reduced cell prolifera-
tion in a dose-dependent manner. As shown in Fig. 4b,
the proliferation of CT26 cells was reduced to 60.13 %
of that of controls in the presence of 1.0 mg/ml GJD.
These results indicate that although GJD is not cyto-
toxic at 1.0 mg/ml, it does inhibit the proliferation of
CT26 cells.
Transwell invasion assays revealed that GJD significantly
inhibited the invasion of CT26 cells at a concentration of
1.0 mg/ml. As shown in Fig. 4c, invasion was 46.12 % of
that of untreated control cells. This result indicates that
GJD inhibited the invasion of CT26 cells regardless of cell
viability.
GJD suppresses tumor growth in a syngeneic mouse
xenograft model
Finally, we examined the effects of GJD on tumor growth
in a mouse tumor xenograft model. Seven days after sub-
cutaneous injection of CT26 cells (2 × 105) into the dorsum
of Balb/c mice, animals were treated with either vehicle
(PBS) or GJD. GJD-treated mice received 333 mg/kg twice
a day, while control group mice were orally administered
with PBS twice a day (Fig. 5a). Tumor progression was then
compared between groups; the results showed that and
GJD inhibited tumor progression (Fig. 5b, c). The average
tumor volume in the control group at Days 7 and 21 was
61.92 mm3 and 1380.76 mm3, respectively, while that in the
GJD group was 53.95 mm3 and 954.08 mm3, respectively.
As shown in Fig. 5d, the average tumor weight in the con-
trol group was 1.00 g, whereas that in the GJD group was
Fig. 4 GJD is not cytotoxic to CT26 cells, but does suppress their proliferation and invasion. a Effects of GJD on the viability of CT-26 cells. CT26 cells
(1 × 104 cells/well) were incubated with 0–1.0 mg/ml GJD for 24 h and cell viability was measured in an MTT assay. b Effect of GJD on the proliferation of
CT-26 cells. CT-26 cells (1 × 104 cells/well) were incubated with 0–1.0 mg/ml GJD for 24 h and proliferation was measured in a BrdU assay. c Effect of GJD
on the invasion of CT-26 cells. CT-26 cells were incubated for 24 h in the presence of vehicle or 1.0 mg/ml GJD and subjected to an invasion assay: upper
wells, 1 × 105 CT-26 cells and 0.2 % BSA; lower wells: serum free medium and fibronectin (10 μl/ml). The histogram represents the number of invading cells,
which was counted in five chosen areas (mean ± SEM, n= 3). An asterisk indicates a significant difference between the GJD and control groups (**P< 0.01)
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0.60 g, although the difference did not reach statistical
significance.
Paeonol is not detected in the aqueous extracts of GJD
GJD comprises Cinnamomi Ramulus, Glycyrrhizae Radix,
Paeoniae Radix, Zingiberis Rhizoma, and Ziziphi Fructus
(Table 1). These five herbs contain phenolic acids, couma-
rins, tannins, flavanones, flavonols, stilbenes, and phenolic
volatile oils, which may have anti-cancer properties
[2]. In particular, paeonol from Paeoniae Radix has anti-
inflammatory and anti-oxidative [24] and anti-angiogenic
and anti-metastatic [25] activities, and inhibits melanoma
metastasis [26]. Thus, we chose paeonol as one of candi-
dates contributing GJD’s anti-tumor activity and asked
whether paeonol might contribute to the anti-invasive
effects of GJD on CRC cells observed in this study. To do
this, we examined chromatograms of GJD by LC-MS
with multiple reaction monitoring mode analysis (from
165m/z to 150m/z and 122m/z) (Fig. 6). Synthesized
paeonol compound was used as a standard for calibration
(Fig. 6a). As paeonol is contained in Paeoniae Radix
[24–26] among the five herbs (Table 1), aqueous extract of
Paeoniae Radix (PE) was included as another control for
detecting paeonol. However, paeonol was not detected
in aqueous PE and GJD extracts even in the concen-
tration of 50 mg/ml, which is about 50 times of con-
centration used in in vitro and in vivo study (Fig. 6b).
Therefore, it appears that the observed anti-tumor
Fig. 5 GJD inhibits tumor growth in a syngeneic mouse tumor model. a Time line for the generation of a mouse tumor xenograft model and
the schedule for GJD treatment. Vehicle (PBS) was orally administered to control mice twice a day. Test mice received 333 mg/kg GJD twice a
day. b Effect of GJD on tumor formation by CT-26 cells. Tumor volumes, measured daily and calculated using the formula width2 × length × 0.5
(length > width), are expressed as the mean ± SEM. Tumors in the GJD group (n = 7) grew more slowly than those in the control group (n = 7).
c Photographs of tumor tissues isolated from each group. d Tumor weights were measured in each group at Day 21. Data are expressed as the
mean ± SEM. GJD inhibited tumor formation by CT-26 cells
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activity of GJD against CRC cells might not be wholly
dependent on paeonol.
Discussion
Many studies have attempted to identify the anti-cancer
effect of various decoctions from traditional Chinese
medical formulations; for example. the effects of Guizhi-
Fuling-decoction on cervical cancer [27], Lichong decoc-
tion on uterine leiomyoma [28], Kuan-Sin-Yin decoction
on bladder and lung cancers [29], ShaoYao decoction on
colitis-associated colorectal cancer [22], Shu-Gan-Liang-
Xue decoction on breast cancer [30], and Jiedu Xiaozheng
Fig. 6 LC-MS chromatograms to detect paeonol in aqueous extract of GJD. The MS analysis was performed in the multiple reaction monitoring
with negative-ion electrospray ionization mode and the transition of m/z 165→ 150, 122 for paeonol. a Blank (methanol; solvent) and paeonol
standard (0.2, 2, 20 μg/ml). b Aqueous extracts of PE (50 mg/ml) and GJD (50 mg/ml). Paeonol was not detected in the PE and GJD extracts
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Yin decoction [31] and Songyou Yin decoction [32] on
hepatoma. Cell motility assays and examination of down-
stream signaling pathways have been used to elucidate
the mechanisms underlying their action in vitro. Also,
tumor-bearing mice models were developed to assess
the ability of decoctions to inhibit tumor growth in vivo.
These decoctions suppress tumor growth both in in vitro
and in vivo [27–32].
GJD contains many components that affect cell moti-
lity, such as cinnamic acid [33], eugenol [34], and 2-hy
droxycinnamaldehyde [35] from Cinnamomi Ramulus;
18β-glycyrrhetinic acid [36] and isoliquiritigenin [37, 38]
from Glycyrrhizae Radix; adenosine [39], betulinic acid
[40], oleanolic acid [41, 42], paeoniflorin [43], paeonol
[25], and α-tocopherol [44] from Paeoniae Radix; gin-
gerol [45–47], and 6-shogaol [48–50] from Zingiberis
Rhizoma. Among these components, we chose paeonol,
which was reported to have anti-tumor activity [25, 26],
as one of candidates to contribute to the anti-invasive
effects of GJD on CRC cells. We thus examined chro-
matograms of aqueous extracts of GJD by LC-MS, but
we did not detect paeonol in the GJD used in this study.
When considering that most phenolic compounds af-
fecting cell motility have very limited water solubility
and GJD is aqueous extract, we suppose that GJD does
not depend on the paeonol for its anti-tumor activity
against CRC cells. However, other unknown constituents
of GJD may mediate the effects against CRC cells ob-
served in this study and further studies should identify the
components of GJD that confer anti-invasive properties.
Metastasis is the main cause of death in CRC patients.
Metastasis comprises many steps; however, inhibition of
cell signaling may be a useful therapy [51]. Here, we
found that GJD (0.3 mg/ml) markedly inhibited the inva-
sion of HCT116, Caco2, and CSC221 CRC cells. More-
over, GJD suppressed expression of p-JNK and p-p38
MAPK. Abnormal MAPK signaling plays a critical role
in cancer progression [52]. Down-regulation of p-JNK
and p-p38 MAPK by GJD may lead to inhibition of
HCT116 invasion. These results are similar to those re-
ported in an advanced study of the ability of GuaLou-
GuiZhi Decoction to inhibit LPS-induced microglial cell
motility by interfering with the MAPK signaling pathway
[53]. p38 MAPK modulates cancer cell invasion and mi-
gration; thus, interfering with this signaling pathway
may inhibit tumor metastasis [54]. Therefore, these re-
sults indicate that GJD inhibits the cell signaling path-
ways associated with invasion, regardless of cell viability.
In this study, we observed that oral administration of
333 mg/kg GJD twice a day inhibited tumorigenesis in
Balb/c mice. The dose was calculated to yield a blood
concentration of 1 mg/ml based on a body weight of
30 g. A previous study showed that cinnamic acid,
hippuric acid, paeoniflorin, and glycyrrhetic acid, all of
which are components of Guizhi decoction (the same
herbal composition but different ratios to GJD), have
half-lives ranging from 1.2 ± 0.3 h to 6.6 ± 2.5 h in rats
[55]. Thus, three or more oral doses per day may be
appropriate; however, we gave the drug twice a day to
minimize the stress to the mice. Taken together, our
present results showed that GJD via oral administration
could delay colorectal tumor progression.
Our present results and other reports provide some
speculation that GJD may be a useful adjuvant therapy
for CRC. First, the relationship between tumorigenesis
and inflammation has been examined in many studies;
these studies provide much genetic, pharmacological,
and epidemiological evidence to support such a link;
also, inflammatory bowel disease is a critical factor for
the progression of colon cancer [15–17]. Second, immune
cells and pro-inflammatory cytokines play important roles
during the development of inflammation-induced cancers;
conversely, colon tumors can induce inflammation of the
colon [56]. Third, inflammatory mediators and components
of the tumor microenvironment influence metastatic events
[57]. Thus, considering the connection between chronic
bowel inflammation and CRC, GJD act similarly to other
decoctions reported to inhibit colorectal tumorigenesis,
e.g., PHY906 [18–21] and SYD [22]. Taken all together,
the data reported herein suggest that GJD may be an
effective adjuvant therapy for CRC.
Conclusions
Here, we show that GJD inhibits the motility of human
CRC cells and suppresses tumorigenesis in a mouse
model. Also, GJD inhibits the p-JNK and p-p38 MAPK
cell signaling pathways, which are associated with inva-
sion, regardless of cell viability. Although further studies
should identify the components that endow GJD with
anti-invasive properties, the present results suggest that
GJD may be a potential adjuvant anti-cancer therapy for
CRC.
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